SGLT2 inhibitors for anemic CKD patients
Treatments studied
Part of Blood & lymphatic, Kidney & urinary clinical trials.
This trial tests whether a diabetes medicine (SGLT2 inhibitor) can help improve anemia in people with chronic kidney disease (CKD). It may be an option if you have mild to moderate kidney disease and stable anemia.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You have chronic kidney disease (CKD) stage 1, 2, 3, or 4.
- Your hemoglobin level is between 8.5 and 12.9 g/dL.
- You have been on a stable treatment plan for your anemia for at least 8 weeks.
- You are not on dialysis and have not had a blood transfusion or change in anemia medication in the last 8 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a medicine called an SGLT2 inhibitor (a type of diabetes drug also used for heart failure) affects the heart and blood vessels in people with kidney failure who are on dialysis. It will help doctors understand if this medicine is safe and helpful for dialysis patients.
This trial tests whether SGLT2 inhibitor drugs can protect kidney function in people with advanced chronic kidney disease who are not yet on dialysis. It may help slow further kidney decline.
This study looks at how well a simple urine test can track chronic kidney disease (CKD) and whether SGLT2 inhibitors (a type of diabetes medicine also used for kidney protection) work in real life. It might help find better ways to manage your condition.
This trial tests a medication called SGLT2 inhibitor (a type of diabetes drug that may also help protect the kidneys) in children with chronic kidney disease. It aims to see if the drug is safe and easy to use in children ages 2–18 with moderate to severe kidney problems.
This trial tests whether a medication called dapagliflozin can help improve anemia in people with chronic kidney disease. If you have moderate to severe kidney disease and low red blood cell counts despite taking standard anemia treatment, this study may explore a new option.
This study tests whether SGLT2 inhibitors (a type of diabetes drug that also helps kidneys) can help patients with acute kidney disease. It may be an option if you have diabetes or chronic kidney disease along with acute kidney problems.
Hear when a new Anemia in CKD Patients trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.